Research programme: receptor tyrosine protein kinase like orphan receptor inhibitorsAlternative Names: ROR1 inhibitors - Oncternal Therapeutics, Inc.
Latest Information Update: 06 Jun 2016
At a glance
- Originator University of California, San Diego
- Developer Oncternal Therapeutics, Inc.; University of California, San Diego
- Class Antibodies; CAR-T cell therapies; Drug conjugates; Monoclonal antibodies
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer